Literature DB >> 8500273

A major portion of polymorphonuclear leukocyte and T lymphocyte migration to arthritic joints in the rat is via LFA-1/MAC-1-independent mechanisms.

A C Issekutz1, T B Issekutz.   

Abstract

The importance of the leukocyte CD11/CD18 beta 2 integrins for leukocyte adhesion and for leukocyte migration to inflamed tissues is well recognized. However, the role of CD11/CD18 molecules and their subtypes, such as LFA-1 and MAC-1, in leukocyte migration to arthritis is not known. Here we report the effects of a new monoclonal antibody (mAb) TA-3, which recognizes and blocks rat LFA-1 (CD11a/CD18), on the migration of 51Cr-labeled rat blood polymorphonuclear leukocytes (PMNL) and 111In-labeled spleen T lymphocytes into the inflamed joints of rats with adjuvant arthritis and to dermal inflammation. The mAb MRC OX-42, which reacts with and blocks rat MAC-1 (CD11b/CD18), was also evaluated. In established arthritis, iv anti-LFA-1 (TA-3) inhibited, up to 50% (P < 0.006) of PMNL accumulation in the talar and metatarsal joints but had no effect on T lymphocyte migration to the joints. In the same animals, anti-LFA-1 partially (35-50%) inhibited PMNL accumulation in acute dermal inflammation induced by zymosan-activated serum (ZAS, C5ades Arg), IL-1 or endotoxin (P < 0.01) and suppressed T lymphocyte migration to dermal DTH, IFN-gamma, LPS, and poly-I:C-induced inflammation by 60-80%. Anti-MAC-1 (OX-42) by itself had no effect on PMNL migration. Anti-MAC-1 combined with anti-LFA-1 did not inhibit PMNL or T lymphocyte migration to joints any more than anti-LFA-1 alone. However, the addition of anti-MAC-1 to anti-LFA-1 further inhibited PMNL migration to acute dermal inflammation by up to 90%. These findings demonstrate that LFA-1 on PMNL plays a major role in PMNL migration but not in T cell migration to arthritic joints. MAC-1 on PMNL appears less important. Furthermore, while LFA-1 and MAC-1 on PMNL and LFA-1 on T lymphocytes mediate much of the migration to dermal inflammation, the migration of these cells to arthritis has a major LFA-1/MAC-1-independent component.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500273     DOI: 10.1006/clin.1993.1073

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease.

Authors:  A C Issekutz; L Ayer; M Miyasaka; T B Issekutz
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 2.  Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.

Authors:  Ioannis Mitroulis; Vasileia I Alexaki; Ioannis Kourtzelis; Athanassios Ziogas; George Hajishengallis; Triantafyllos Chavakis
Journal:  Pharmacol Ther       Date:  2014-11-14       Impact factor: 12.310

Review 3.  Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis.

Authors:  E Paleolog
Journal:  Mol Pathol       Date:  1997-10

4.  Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas.

Authors:  Q Tang; R L Hendricks
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

5.  Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms.

Authors:  A C Issekutz; T B Issekutz
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

6.  Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation.

Authors:  T B Issekutz; M Miyasaka; A C Issekutz
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

Review 7.  Manipulation of cell surface macromolecules by flaviviruses.

Authors:  Robert Anderson
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.